Anzeige
Mehr »
Login
Mittwoch, 04.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Analysten eilen, um Kursziele zu verdreifachen nach ATHAs neuester Entdeckung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Edison Investment Research-Archiv vom 20.03.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
20.03.Braemar - Diversification paying dividends367Braemar's FY24 trading update was in line with expectations, with revenues of c £150m and underlying operating profit of c £18m. Underlying operations continue to expand and diversify and the company...
► Artikel lesen
20.03.Boku - Making the complex simple for global merchants475Boku's strategy to widen its offering within the local payment method (LPM) market accelerated FY23 revenue growth to 30%, with 15% growth from the core direct carrier billing (DCB) business and supplemented...
► Artikel lesen
20.03.Tinexta - Strongest year since FY18297Tinexta enjoyed its strongest year for underlying profit growth in FY23 since FY18 which, given the recent challenging macro environment, is testimony to the changes in its business portfolio. Management...
► Artikel lesen
20.03.Newron Pharmaceuticals - Evenamide set for a pivotal year581Newron Pharmaceuticals has reported results for FY23, an active period for its lead asset, evenamide, being developed for treatment-resistant schizophrenia (TRS) and poorly managed schizophrenia (non-TRS)....
► Artikel lesen
20.03.IRLAB Therapeutics - Mesdopetam's potential highlighted in PD-psychosis240The recent scientific paper in Neurotherapeutics discusses the encouraging preclinical studies focused on the characterisation of the neurophysiological brain state in Parkinson's disease psychosis...
► Artikel lesen
20.03.The Biotech Growth Trust - Onwards and upwards for performance recovery231The Biotech Growth Trust's (BIOG's) two co-managers, Geoff Hsu and Josh Golomb, at global healthcare specialist OrbiMed, believe that now could be an opportune time to consider the biotech sector as...
► Artikel lesen